PD-1 Antikörper

Produktnummer ABIN2689142

Produktdetails anti-PD-1 Antikörper

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Blocking Reagent (BR)

Marke: BD Pharmingen™

Produktmerkmale: The EH12.1 monoclonal antibody specifically binds to CD279. CD279 is an immunoregulatory receptor that is expressed on activated T cells, B cells and myeloid cells and contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region. Mice deficient in CD279 show a breakdown of peripheral tolerance and manifest multiple autoimmune symptoms. PD-L1 and PD-L2 are ligands of CD279 and are members of the B7 gene family. Interaction of CD279:PD-Ligands results in inhibition of T cell proliferation and cytokine secretion. Reports suggest that the B7/CTLA-4 pathway functions primarily to attenuate, limit, and/or terminate naive T-cell activation in secondary lymphoid organs. The PD-ligand:CD279 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery.

BD Pharmingen™ Purified NA/LE Mouse anti-Human CD279 (PD-1) - NA/LE - Clone EH12.1 (also known as EH12) - Isotype Mouse IgG1, κ - Reactivity Hu - 0.5 mg

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterilität: Sterile filtered,0.2 μm filtered

Endotoxin-Niveau: Endotoxin level is ≤0.01 EU/μg (≤0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Human PD-1 Recombinant Protein

Klon: EH12-1

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Konservierungsmittel: Without preservative

Handhabung: This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Referenzen für anti-PD-1 Antikörper (ABIN2689142)

Velu, Kannanganat, Ibegbu, Chennareddi, Villinger, Freeman, Ahmed, Amara: "Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination." in: Journal of virology, Vol. 81, Issue 11, pp. 5819-28, (2007) (PubMed).

Dorfman, Brown, Shahsafaei, Freeman: "Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma." in: The American journal of surgical pathology, Vol. 30, Issue 7, pp. 802-10, (2006) (PubMed).

Bennett, Luxenberg, Ling, Wang, Marquette, Lowe, Khan, Veldman, Jacobs, Valge-Archer, Collins, Carreno: "Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 2, pp. 711-8, (2003) (PubMed).

Kanai, Totsuka, Uraushihara, Makita, Nakamura, Koganei, Fukushima, Akiba, Yagita, Okumura, Machida, Iwai, Azuma, Chen, Watanabe: "Blockade of B7-H1 suppresses the development of chronic intestinal inflammation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 171, Issue 8, pp. 4156-63, (2003) (PubMed).

Carter, Fouser, Jussif, Fitz, Deng, Wood, Collins, Honjo, Freeman, Carreno: "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2." in: European journal of immunology, Vol. 32, Issue 3, pp. 634-43, (2002) (PubMed).

Latchman, Wood, Chernova, Chaudhary, Borde, Chernova, Iwai, Long, Brown, Nunes, Greenfield, Bourque, Boussiotis, Carter, Carreno, Malenkovich, Nishimura, Okazaki, Honjo, Sharpe, Freeman: "PD-L2 is a second ligand for PD-1 and inhibits T cell activation." in: Nature immunology, Vol. 2, Issue 3, pp. 261-8, (2001) (PubMed).

Freeman, Long, Iwai, Bourque, Chernova, Nishimura, Fitz, Malenkovich, Okazaki, Byrne, Horton, Fouser, Carter, Ling, Bowman, Carreno, Collins, Wood, Honjo: "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation." in: The Journal of experimental medicine, Vol. 192, Issue 7, pp. 1027-34, (2000) (PubMed).

Nishimura, Minato, Nakano, Honjo: "Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses." in: International immunology, Vol. 10, Issue 10, pp. 1563-72, (1999) (PubMed).

Details zu PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Andere Bezeichnung: CD279 PD-1 (PDCD1 Produkte)

Synonyme: CD279 antikoerper, PD-1 antikoerper, PD1 antikoerper, SLEB2 antikoerper, hPD-1 antikoerper, hPD-l antikoerper, Ly101 antikoerper, Pdc1 antikoerper, programmed cell death 1 antikoerper, PDCD1 antikoerper, Pdcd1 antikoerper

Hintergrund: Synonyms: hPD-1, PD1, PDCD1, Programmed cell death 1, SLEB2

Pathways: Cancer Immune Checkpoints